Using FY2023 as a baseline, the pharmaceutical business
has committed to aggressive goals for reducing greenhouse gas (GHG) emissions,
including a 42% decrease in absolute Scope 1, 2, and 3 emissions by fiscal year
2030. By fiscal year 2050, the company wants to achieve net-zero emissions
throughout its whole value chain and switch to 100% renewable electricity.With operations in the US, UK, and India,
Granules is a vertically integrated pharmaceutical company that provides
services to more than 300 clients in more than 80 countries.
The business has regulatory
permits from several international health agencies and operates production
sites in the US and India. The company’s proactive
approach to tackling climate change in the pharmaceutical industry and its
strategic focus on sustainable business practices are highlighted by the
validation.